ackground and Aims Limited information is available on long-term outcomes of EUS-guided gastroenterostomy (EUS-GE) and modifications of lumen-apposing metal stents (LAMSs) over time. Methods All consecutive EUS-GEs for malignant indications between 2020 and 2024 were enrolled in a single-center prospective registry (Prospective Registry of Therapeutic, ClinicalTrials.gov NCT04813055). The primary outcomes were EUS-GE dysfunctions and dysfunction-free survival (DyFS) using Kaplan-Meier curves. Endoscopic and radiologic reassessments were used to estimate local modifications and LAMS diameter over time (linear regression). Results A total of 166 EUS-GEs (median age 66 [IQR, 60-73] years; male 53.6%; pancreatic cancer, 74.1%) were included. A 20-mm LAMS dilated to 18 mm was used in 98.8%. Technical and clinical success rates were 98.8% and 95.7%, respectively. Adverse events were registered in 16.3% (procedure-related, 7.2%). Over a median follow-up of 128 (64-245) days, symptom recurrence occurred in 11%, but was related to EUS-GE dysfunctions in 13 of 154 cases (8.4%), after a median of 209 (85-347) days. All endoscopic reinterventions were successful. Estimated DyFS at 6 and 12 months was 96.7% and 82%, respectively. At endoscopic re-evaluations (47 patients, 61 endoscopies), peri-LAMS tissue reactions were observed in 38.3% after 269 (79-390) days whereas LAMS modifications (mostly ingrowth) were observed in 19.1% after 421 (231-560) days. Radiologic follow-up (89 patients, 168 CT scans) revealed a reduction in LAMS diameter of ≈0.21 mm ± 0.03 every month (F test; P < .0001). Conclusions Clinically overt EUS-GE dysfunctions are rare and successfully endoscopically amenable, discouraging scheduled surveillance in malignancies. However, LAMSs show predictable narrowing, sustained by subclinical local reactions, which might inform surveillance in benign indications.

Long-term Outcomes of endoscopic ultrasound-guided Gastroenterostomy (LONG-RANGE study): a prospective cohort study tracking symptom recurrence, reintervention timelines and stent modifications over time / Vanella, G., Frigo, F., Perelli, F., Barà, R., Leone, R., Stasio, R.c., Maisonneuve, P., Partelli, S., Aleotti, F., Orsi, G., Macchini, M., Balzano, G., Reni, M., Falconi, M., Capurs, G., Arcidiacono, P.g.. - In: GASTROINTESTINAL ENDOSCOPY. - ISSN 0016-5107. - (2026), pp. 242-252. [10.1016/j.gie.2026.01.007]

Long-term Outcomes of endoscopic ultrasound-guided Gastroenterostomy (LONG-RANGE study): a prospective cohort study tracking symptom recurrence, reintervention timelines and stent modifications over time

Vanella G
Primo
;
Leone R;Partelli S;Aleotti F;Orsi G;Reni M;Falconi M;Capurs G
Penultimo
;
Arcidiacono PG
Ultimo
2026-01-01

Abstract

ackground and Aims Limited information is available on long-term outcomes of EUS-guided gastroenterostomy (EUS-GE) and modifications of lumen-apposing metal stents (LAMSs) over time. Methods All consecutive EUS-GEs for malignant indications between 2020 and 2024 were enrolled in a single-center prospective registry (Prospective Registry of Therapeutic, ClinicalTrials.gov NCT04813055). The primary outcomes were EUS-GE dysfunctions and dysfunction-free survival (DyFS) using Kaplan-Meier curves. Endoscopic and radiologic reassessments were used to estimate local modifications and LAMS diameter over time (linear regression). Results A total of 166 EUS-GEs (median age 66 [IQR, 60-73] years; male 53.6%; pancreatic cancer, 74.1%) were included. A 20-mm LAMS dilated to 18 mm was used in 98.8%. Technical and clinical success rates were 98.8% and 95.7%, respectively. Adverse events were registered in 16.3% (procedure-related, 7.2%). Over a median follow-up of 128 (64-245) days, symptom recurrence occurred in 11%, but was related to EUS-GE dysfunctions in 13 of 154 cases (8.4%), after a median of 209 (85-347) days. All endoscopic reinterventions were successful. Estimated DyFS at 6 and 12 months was 96.7% and 82%, respectively. At endoscopic re-evaluations (47 patients, 61 endoscopies), peri-LAMS tissue reactions were observed in 38.3% after 269 (79-390) days whereas LAMS modifications (mostly ingrowth) were observed in 19.1% after 421 (231-560) days. Radiologic follow-up (89 patients, 168 CT scans) revealed a reduction in LAMS diameter of ≈0.21 mm ± 0.03 every month (F test; P < .0001). Conclusions Clinically overt EUS-GE dysfunctions are rare and successfully endoscopically amenable, discouraging scheduled surveillance in malignancies. However, LAMSs show predictable narrowing, sustained by subclinical local reactions, which might inform surveillance in benign indications.
File in questo prodotto:
File Dimensione Formato  
PIIS0016510726000349.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Tutti i diritti riservati
Dimensione 11.62 MB
Formato Adobe PDF
11.62 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/196477
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact